MF59佐剂四价流感疫苗与无佐剂疫苗在儿童中的疗效、免疫原性和安全性比较
这项多中心、随机、观察者盲法3期试验在9个国家146个中心纳入6月龄至5岁儿童,比较MF59佐剂四价灭活流感疫苗(aIIV4)与无佐剂流感疫苗。aIIV4对全部四个疫苗株及三个异源株免疫应答更优,安全性相似但征集性不良事件更频繁。
要点
- aIIV4对四个疫苗株及三个异源株的GMT比值均高于对照疫苗。
核心结论
- 整体研究人群中aIIV4较美国获批无佐剂流感疫苗无额外获益。
- 在6-23月龄预设亚组中aIIV4较无佐剂疫苗提供更高保护。
- aIIV4与对照疫苗在6月龄至5岁儿童中效力与安全性特征相似。
研究设计与样本
- 多中心、随机对照、观察者盲法3期试验,覆盖9个国家146个中心。
- 纳入6月龄至5岁儿童,按1:1随机分配至aIIV4或无佐剂灭活流感疫苗(IIV3或IIV4)。
- 主要结局为RT-PCR确诊任何流感株所致流感的相对疫苗效力。
主要发现
- 征集性不良事件aIIV4组3748/5138(73%)高于对照组3242/5056(64%)。
关键数值与推荐
- 疫苗未接种者共接种2剂(第1天和第29天),已接种者仅第1天接种1剂。
临床怎么用
- 在6-23月龄婴幼儿中可优先考虑MF59佐剂四价流感疫苗以增强保护。
- 整体6月龄至5岁儿童中aIIV4与无佐剂疫苗效力相当,选择时需结合年龄亚组。
- 接种aIIV4后征集性不良事件更常见,需做好家长告知。
局限性
- 整体人群未显示aIIV4额外获益,仅6-23月龄亚组显著。
- 原文未报告其他年龄亚组相对疫苗效力的详细数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Young children have immature immune systems and respond poorly to standard influenza vaccines. The oil-in-water emulsion adjuvant MF59 can increase antigen uptake, macrophage recruitment, lymph node migration, and avidity to influenza virus. Therefore, we aimed to assess the relative efficacy, immunogenicity, and safety of an MF59-adjuvanted, quadrivalent, inactivated (subunit) influenza vaccine (aIIV4) compared with a US-licensed non-adjuvanted influenza vaccine in children. METHODS: We did a multicentre, randomised controlled, observer-blinded, phase 3 trial of 146 sites including hospitals, clinics, and clinician offices in nine countries over two influenza seasons. We included children of either sex aged 6 months through 5 years. We stratified eligible participants and randomly assigned them (1:1), using a block size of four, to receive either aIIV4 or non-adjuvanted inactivated influenza vaccine (ie, trivalent inactivated influenza vaccine [IIV3] or quadrivalent inactivated influenza vaccine [IIV4]). We masked participants, parents or guardians, and outcome assessors to the administered vaccine. Designated personnel who were not masked administered aIIV4 in both seasons, or IIV3 in season one and IIV4 in season two. All vaccinations were administered intramuscularly. Children aged 6 through 35 months received one or two 0·25 mL doses, whereas those aged 3 through 5 years received one or two doses of 0·5 mL. The number of doses was dependent on previous vaccination status: vaccine-naive participants received a total of two doses of study vaccine, the first on day 1 and the second on day 29, whereas non-naive participants received only one dose on day 1. The primary outcome was relative vaccine efficacy assessed by RT-PCR-confirmed influenza due to any influenza strain in the overall study population and in prespecified age and dose subgroups. Immunogenicity against homologous and heterologous strains of influenza and safety were also measured. This study is registered with ClinicalTrials.gov, number NCT01964989. FINDINGS: Between Nov 3, 2013, and March 5, 2014 (season one), and between Sept 30, 2014, and March 29, 2015 (season two), 10 644 participants were enrolled in this study. Of these participants, 10 612 were vaccinated (n=5338 with aIIV4 and n=5274 with comparator). Relative vaccine efficacy was not different between aIIV4 and the comparator vaccines in the overall study population (relative vaccine efficacy -0·67, 95% CI -19·81 to 15·41). The relative vaccine efficacy in the 6 through 23-month subgroup was significantly greater for aIIV4 than for the comparator vaccine (relative vaccine efficacy 31·37, 95% CI 3·14-51·38). aIIV4 elicited superior immunogenic response compared with the comparator for all four vaccine strains (geometric mean titre ratios 1·91 [95% CI 1·8-2·0] for A/H1N1, 1·71 [1·6-1·8] for A/H3N2, 2·19 [2·0-2·4] for B/Yamagata, and 2·27 [2·0-2·6] for B/Victoria) and three heterologous strains (1·94 [1·6-2·3] for A/H3N2, 2·17 [1·8-2·6] for B/Yamagata, and 2·12 [1·6-2·7] for B/Victoria) in participants aged 6 months through 5 years. The highest geometric mean titre ratios were observed in participants aged 6 through 23 months. Safety profiles were similar but more frequent solicited adverse events were reported with aIIV4 than with the comparator (3748 [73%] of 5138 vs 3242 [64%] of 5056). INTERPRETATION: Although there was no additional benefit of aIIV4 compared with the US-licensed non-adjuvanted influenza vaccines in the overall study population, in the youngest and most vulnerable population of children in this trial, aIIV4 provided greater protection against influenza than a non-adjuvanted vaccine when assessed in this prespecified age group of 6 through 23 months. Additional clinical benefit was also apparent early after first vaccination in vaccine-naive participants aged 6 months through 5 years. Finally, aIIV4 and comparator had similar efficacy and vaccine safety profiles in children aged 6 months through 5 years. FUNDING: Seqirus UK Ltd.
引用
- Vesikari T, Kirstein J, Devota Go G, et al. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Lancet Respir Med. 2018. PMID: 29631857. doi:10.1016/S2213-2600(18)30108-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。